Skip to main content
Clinical Trials/NCT02831101
NCT02831101
Completed
Not Applicable

Impact of Sufentanil on the Depth of Sedation Measured by Bispectral Index During Induction of Anaesthesia With Propofol in the Elderly - a Randomised Trial

University Hospital, Geneva0 sites71 target enrollmentFebruary 2012

Overview

Phase
Not Applicable
Intervention
Sufentanil
Conditions
Loss of Consciousness
Sponsor
University Hospital, Geneva
Enrollment
71
Primary Endpoint
BIS and propofol
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

We compared BIS values during propofol stepwise induction with or without concomitant sufentanil in patients ≥ 65 years .

Detailed Description

Bispectral index (BIS) is widely used to estimate the depth of anesthesia. In clinical studies, a large variability of BIS has been observed. Several factors may be responsible for this inconsistency. We were able to show that in elderly patients (average age 78 years) receiving increasing doses of propofol alone a BIS values at loss of consciousness (LOC) were about 30% higher compared with young patients (average age 35 years). We showed also that in young patients (average age 48 years) the BIS values at LOC were significantly higher in those receiving sufentanil concomitantly with propofol compared with those who had received propofol alone. It remains unknown, however, whether these data from young surgical patients are applicable to a population of elderly patients. It may be argued that in the elderly receiving propofol, the impact of advance age was so important that any addition of an opioid would not further disturb the sedation-monitor balance. Alternatively, it may be expected that in the elderly receiving an opioid added to propofol the impact of both drugs on sedation will be additive and that previous observations from younger patients will be further exaggerated. The impact of advance age and presence or absence of sufentanil during propofol induction on BIS values at LOC was investigated in this trial.

Registry
clinicaltrials.gov
Start Date
February 2012
End Date
November 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christopher Lysakowski

MD PD

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

  • Age ≥65 years

Exclusion Criteria

  • History of heart disease
  • History of renal disease
  • History of psychiatric
  • Allergy to propofol or sufentanil

Arms & Interventions

Sufentanil

Sufentanil intravenously, continuously with effect-site concentration of 0.3 ng/ml until the end of the study

Intervention: Sufentanil

Placebo

Saline intravenously, continuously with the same effect-site concentration as sufentanil (recorded on administration device) until the end of the study

Intervention: Placebo

Outcomes

Primary Outcomes

BIS and propofol

Time Frame: BIS values after steady state concentration of propofol

Propofol was administrated step-wise by increasing concentration of 0.5mcg/ml (0.5, 1.0, 1.5 etc.). After each steady state that was kept during 5 min, BIS values were recorded

BIS at baseline

Time Frame: BIS values at baseline before administration of any study drugs

BIS values in awake patient in supine position, eyes closed, quiet environment

BIS and sufentanil

Time Frame: BIS values 10 min after steady state concentration of sufentanil

BIS values recorded after the steady state concentration was obtained and kept during 10min.

BIS and LOC

Time Frame: BIS values at loss of consciousness

BIS values were recorded at LOC, that was estimated using a OAA/S scale, a 0-5 point scale, 5 corresponds to a fully awake state, a score of 0 to a completely unresponsive state. A score \<2 (absence of response to mild prodding or shaking was regarded as LOC. Blinded to study drug investigator evaluated all sedation scores.

Similar Trials